SCHEMBL3097335

SCHEMBL3097335

COc1ccc(CN2[C](Cl)Cc3ccccc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
CASP3 P42574 2/20 0.56
KMT2A Q03164 2/20 0.56
GAA P10253 2/20 0.56
APAF1 O14727 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.54
NOD1 Q9Y239 1/20 0.51
SMPD1 P17405 2/20 0.50
SIGMAR1 Q99720 1/20 0.50
CMA1 P23946 1/20 0.50
GSK3B P49841 2/20 0.47
GSK3A P49840 1/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 2/20 0.47
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3088630 0.87 MEN1 (0.54) MEN1CASP3KMT2AGAAAPAF1
SCHEMBL14938439 0.85 MEN1 (0.71) MEN1CASP3KMT2AGAAAPAF1
SCHEMBL3078219 0.83 NOD1 (0.55) MEN1KMT2AGAANOD1MAPT
SCHEMBL3088030 0.83 NOD1 (0.55) MEN1KMT2ANOD1SIGMAR1TSHR
SCHEMBL3084691 0.80 NOD1 (0.52) MEN1KMT2AGAANOD1ALDH1A1
SCHEMBL3085739 0.79 NOD1 (0.51) MEN1KMT2ANOD1ALDH1A1SMN1; SMN2
SCHEMBL30100689 0.78 POLB (0.71) MEN1CASP3KMT2AGAAAPAF1
SCHEMBL4328336 0.78 POLB (0.71) MEN1CASP3KMT2AGAAAPAF1
SCHEMBL30100692 0.78 POLB (0.71) MEN1CASP3KMT2AGAAAPAF1
SCHEMBL3408919 0.78 CASP3 (0.52) MEN1CASP3KMT2AGAAAPAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207134-B2 Fused ring spiroketal derivative and use thereof as anti-diabetic drug CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-06-26 US disclosed
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-09-16 US disclosed
EP-2048152-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234609-A1 FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG REN, WNK1, GCKR MEN1 2579/4885CASP3 1223/4885KMT2A 4219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.